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The phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are an important family of
enzymes, whose physiological roles are being teased out by a variety of means. Phos-
phatidylinositol-5-phosphate 4-kinase g (PI5P4Kg) is especially intriguing as its in vitro
activity is very low. Here we review what is known about this enzyme and discuss some
recent advances towards an understanding of its physiology. Additionally, the effects of the
ATP-competitive inhibitor I-OMe Tyrphostin AG-538 on all three mammalian PI5P4Ks was
explored, including two PI5P4Kg mutants with altered ATP- or PI5P-binding sites. The
results suggest a strategy for targeting non-ATP binding sites on inositol lipid kinases.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).Contents
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1.1. The PI5P4Ks
The phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are a family consisting of three isoforms in mammals (a, b, and
g), whose most likely function is currently believed to be the regulation of the levels of their substrate, PI5P (see refs (Bulley
et al., 2015; Clarke and Irvine, 2012; Clarke et al., 2010) for reviews). This view stems from the comparatively low levels of its
substrate, PI5P, compared to the amounts of PI4P, the substrate of the PI4P5Ks, which synthesise the bulk of the cell's PI(4,5)P2
(see for example, (Clarke et al., 2001; Roberts et al., 2005)). Some recent work from our laboratory (S. Bulley et al., unpub-
lished) has pointed to the possibility that synthesis of a local, minor pool of PI(4,5)P2 might be a physiologically signiﬁcant
function of PI5P4Ka.
The a and b isoforms have been assigned some physiological and pathological functions, which include roles in gene
regulation (Gelato et al., 2014; Shah et al., 2013), stress responses (Keune et al., 2013), insulin signalling (Lamia et al., 2004)
and cancer (Emerling et al., 2013; Fitzgerald and McCubrey, 2014; Jude et al., 2014) e see (Fiume et al., 2015) for review. Also,
PI5P generated during bacterial infection has been shown to have a function in regulating that process, primarily by altering
cytoskeletal function (Niebuhr et al., 2002; Ramel et al., 2011).
1.2. PI5P
Physiological roles for PI5P associated with the cytoskeleton have also been reported (reviewed in detail in (Bulley et al.,
2015)). For example, overexpression of the PI5P-generating enzyme PIKfyve or microinjection of PI5P mimics insulin's effects
on F-actin stress ﬁbres (Sbrissa et al., 2004), and studies from Wesche's lab (Haugsten et al., 2013; Oppelt et al., 2014, 2013)
imply that PI5P is a signalling intermediate in FGF1-stimulated cell migration. FGF1 induces PI5P production and promotes
cell migration in BJ ﬁbroblasts (Oppelt et al., 2013), effects that are attenuated by knockdown of the PI5P-generating enzymes
PIKfyve and MTMR3. Moreover, overexpressing PI5P4Ka in order to deplete cellular PI5P decreases cell migration velocity
(Haugsten et al., 2013), while Rac has been shown to be an effector of these effects, whichmay contribute to cell migration and
metastasis (Oppelt et al., 2014). Recently, PI5P has been implicated in autophagy (Vicinanza et al., 2015).
Nuclear functions of PI5P have also clearly indicated (Bulley et al., 2015), with two important effectors being ING-2 (Bua
et al., 2013; Gozani et al., 2003) and UHRF1 (Gelato et al., 2014). Given that both PI5P4Ks a and b are found in the nucleus
(Bultsma et al., 2010; Ciruela et al., 2000; Wang et al., 2010), it remains unclear as the relative contributions of these PI5P4Ks
to these events (though the contribution of PI5P4Kb to stress responses in the nucleus has been clearly shown (Jones et al.,
2006)).
2. PI5P4Kg
2.1. Background
This is currently the least understood of the PI5P4K isoforms. It is apparently ubiquitously expressed, but at very different
levels between tissues, being particularly high in epithelial cells of the thick ascending limb of the kidney and collecting duct
cells (Clarke et al., 2008) and in speciﬁc neurons in brain (Clarke et al., 2009). It apparently has a vesicular localization (Clarke
et al., 2008, 2009), which we have recently conﬁrmed by GFP-tagging the enzyme using CRISPR-Cas-9 technology in mpkCCD
cells (M-L.G. & R.F.I. unpublished). PI5P4Kg has been reported to have a speciﬁc (not shown by PI5P4Ks a or b) functional
connectionwith Rho (Yih et al., 2012). Also some compelling evidence has recently linked PI5P4Kg to mTORC1 (Mackey et al.,
2014). mTORC1 phosphorylates PI5P4Kg, causing it to change its cellular localisation, and PI5P4Kg exerts a regulatory in-
ﬂuence on mTORC1 (which is in turn changed if it is phosphorylated), shown most clearly in Tsc2 knocked-down cells
(Mackey et al., 2014).
One of the most puzzling features of PI5P4Kg is that it has a much lower enzymatic activity in vitro than the other PI5P4K
isoforms, which we have shown lies primarily at the ATP binding site, as if this is incrementally mutated to resemble the
PI5P4Ka ATP site, the enzyme shows increasing activity (Clarke and Irvine, 2013). PI5P4Kg can heterodimerise in vitro with
PI5P4Ka (Clarke and Irvine, 2013), and as extensive heterodimerisation between PI5P4Ks a and b has been shown to occur
in vivo (Bultsma et al., 2010; Wang et al., 2010), a potential function for PI5P4Kg as a ‘targeting’ protein for the other two
(much more active) though our more recent investigations (below) have made this hypothesis appear increasingly unlikely.
2.2. Inhibition
Our own recent investigations of PI5P4Kg have used RNAi knockdown and a very speciﬁc inhibitor, NIH-12848, which
interacts with the PI5P-binding site of PI5P4Kg (Clarke et al., 2015). The removal of PI5P4Kg by RNAi (but not removal of
PI5P4Ks a or b) closely mimics the effects of the inhibitor in preventing the formation of the polarised phenotype that
mpkCCD cells adopt, including localisation of the Naþ/Kþ ATPase and formation of domes on the culture dish. This phenotype
is superﬁcally consistent with the polarised distribution of PI5P4Kg in epithelial cells in the kidney in vivo (Clarke et al., 2008).
Fig. 1. Effect of 20 mM AG-538 on PI5P4K recombinant enzymes. Enzymes were prepared and assayed as in (Clarke and Irvine, 2013) and (Clarke et al., 2015). Data
(mean of triplicates) show the residual activity of each enzyme (as %) compared to the absence of inhibitor.
M.-L. Giudici et al. / Advances in Biological Regulation 61 (2016) 47e50 493. Inhibiting PI5P4Ks
Speciﬁc inhibitors of enzymes can be useful tools in studying their function, and the fortuitous discovery of such a speciﬁc
inhibitor for PI5P4Kg will be of great value in the future. The recent characterization of inhibitors for PI5P4Ka (Davis et al.,
2013) and PI5P4Kb (Voss et al., 2014) have raised that hope for those isoforms too, but the isoform speciﬁcity of neither
inhibitor has yet been established. Moreover, a challenge facing ATP-binding site inhibitors (the majority), is for them to have
both sufﬁcient speciﬁcity (because all kinase ATP binding sites show some structural similarity) and potency (cellular con-
centrations of ATP are in themillimolar range, so nanomolar afﬁnity of an inhibitor is often required formicromolar efﬁcacy in
a cell).
Designing PI5P4Ka and PI5P4Kb inhibitors to bind instead to the PI5P binding site, as NIH-12848 does to PI5P4Kg, might
move us a signiﬁcant step closer to pharmaceutical application. The PI5P4Kgmutated so that its ATP site is similar to PI5P4Ka
(PI5P4Kg þ (Clarke and Irvine, 2013)) might be a valuable tool in this respect, as, for example, any inhibitor emerging from a
PI5P4Ka screen could be immediately tested against PI5P4Ks b and g (for isoform speciﬁcity) and also PI5P4Ks bþ and gþ
(Clarke and Irvine, 2013). Any compound that inhibits these latter two with an efﬁcacy similar to that on PI5P4Ka could be
eliminated as likely to be interacting with the ATP-binding site, whereas any showing a similar isoform speciﬁcity to the wild
type PI5P4Ks b and g is probably interacting with the PI5P site or an allosteric site.
We have carried out a simple proof of principle experiment to address this idea using the PI5P4Ka inhibitor I-OMe Tyr-
phostin AG-538 (Davis et al., 2013), which targets the ATP site. We looked at the inhibition of the three PI5P4K isoforms, and
also two mutant PI5P4Kgs: PI5P4Kgþ, which has its ATP site mutated to be similar to that of PI5P4Ka (Clarke and Irvine,
2013), and PI5P4Kg N165I, which is mutated in the PI5P-binding site to make it resistant to NIH-12848 (Clarke et al.,
2015). The data (Fig. 1) show that at a concentration of 20 mM, AG-538 induces an almost complete inhibition of PI5P4Ka,
inhibits PI5P4Ks b and g by 90% and 85% respectively, indicating that although it favours PI5P4Ka, it is not very isoform
speciﬁc (compare NIH-12848 against PI5P4Kg (Clarke et al., 2015)). However, the most interesting observation from these
data is that PI5P4Kgþ is, as we would expect, as sensitive to AG-538 inhibition as is PI5P4Ka, while PI5P4Kg N165I is exactly
the same asWT PI5P4Kg. On this basis, AG-538 would be eliminated from the screen as being likely binding to the ATP site of
PI5P4Ka, which it does.
Thus these data support a simple proof of principle that inhibitors for PI5P4Ka that interact through sites different from
the ATP-binding site can be discovered using PI5P4Kgþ (and PI5P4Kbþ, generated on the same logic as PI5P4Kgþ (Clarke and
Irvine, 2013)) as screening tools. The remarkable speciﬁcity of NIH-12848 for PI5P4Kg that we have demonstrated (Clarke
et al., 2015) is certainly something that would be valuable to replicate for the other PI5P4K isoforms.Acknowledgements
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